J
2024
Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of early-stage breast cancer: prospective randomized study
BURKOŇ, Petr, Iveta SELINGEROVÁ, Marek SLÁVIK, Miloš HOLÁNEK, Miroslav VRZAL et. al.
Basic information
Original name
Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of early-stage breast cancer: prospective randomized study
Authors
BURKOŇ, Petr, Iveta SELINGEROVÁ, Marek SLÁVIK, Miloš HOLÁNEK, Miroslav VRZAL, Oldřich COUFAL, Kateřina POLÁCHOVÁ, Petr MULLER, Pavel ŠLAMPA and Tomáš KAZDA
Edition
Radiation Oncology, BMC, Elsevier, 2024, 1748-717X
Other information
Type of outcome
Article in a journal
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
is not subject to a state or trade secret
Organization
Lékařská fakulta – Repository – Repository
EID Scopus
2-s2.0-85184096089
Keywords in English
Early breast cancer; Adjuvant radiotherapy; Surgical bed; APBI; External beam radiotherapy
Links
LX22NPO5102, research and development project. BBMRI.cz IV, large research infrastructures. CZECRIN IV, large research infrastructures.
V originále
gt;= 2 late skin toxicity was observed (p = 0.026). Late toxicity in the breast area (deformation, edema, fibrosis, and pain), affecting the quality of life and cosmetic effect, occurred in 61% and 17% of patients in WBI and APBI arms, respectively. The cosmetic effect was more favorable in the APBI arm, especially 6 to 12 months after the radiotherapy.ConclusionExternal APBI demonstrated better feasibility and less toxicity than the standard regimen in the adjuvant setting for treating early breast cancer patients. The presented study confirmed the level of evidence for establishing the external APBI in daily clinical practice.Trial registrationNCT06007118.
Displayed: 15/6/2025 10:37